Private equity firm RA Capital Management led a $115m Series C round in Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, with participation from Boxer Capital, HBM Healthcare Investment, Lilly Asia Ventures and Qiming Venture Partners. "Connect is focused on innovating best-in-class therapies to address patient need globally, and our ability to attract top-tier global investors is important validation of the potential value of our pipeline and its underlying technologies. We believe that our wholly-owned and growing pipeline, technology, scientific and clinical expertise, and world-class investors position us for success in continued execution of our near-term objectives and attaining our long-term vision of improving care and outcomes for patients with inflammatory and autoimmune disease," Zheng Wei, Connect Co-Founder and CEO.